Jubilant Pharmova will host a series of physical meetings with institutional investors in Mumbai on August 13 and 14, 2026. The management team will engage with key market participants to discuss the company’s financial performance and strategic outlook following the release of its first-quarter results.

The meetings are organized by Emkay Global Financial Services as part of their Flagship Conference, Emkay Confluence. These engagements serve as a platform for the company to communicate directly with analysts and fund managers regarding its operational updates and financial metrics for the period.

The primary agenda for these interactions is the Q1FY27 Earnings presentation. Jubilant Pharmova is scheduled to file its Q1FY27 financial results on August 10, 2026. The subsequent investor meetings aim to provide deeper context to the reported figures and address queries from the investment community.

The company has invited several prominent asset management companies and insurance firms for these sessions. The schedule includes one-on-one and group formats, allowing for detailed discussions tailored to specific investor interests. However, the management noted that the schedule may undergo changes due to exigencies on the part of investors, analysts, or the company.

Participating Institutions

The following entities have been invited to participate in the investor meetings:

This disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Naresh Kapoor, Company Secretary of Jubilant Pharmova Limited, signed the intimation on August 5, 2026.

What This Means for Investors

The timing of these meetings immediately following the Q1FY27 results filing indicates a focus on transparency regarding the company's recent performance. For shareholders and potential investors, these sessions offer an opportunity to gain management's perspective on revenue drivers, margin trends, and forward-looking guidance for the remainder of FY27. The presence of major asset managers like HDFC AMC and ICICI Prudential suggests significant institutional interest in the company's near-term trajectory.

Jubilant Pharmova has postponed its board meeting scheduled to consider the first quarter of FY26 financial results. The company announced on August 5, 2026, that the meeting originally set for Friday, August 7, 2026, has been rescheduled to Monday, August 10, 2026, due to unavoidable circumstances. This delay means investors will receive the Q1FY26 standalone and consolidated financial statements later than initially planned.

The postponement is governed by the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board of Directors will use the rescheduled session to approve the unaudited financial results for the quarter ended June 30, 2026. No specific reason beyond "unavoidable circumstances" was provided in the intimation filed with BSE Limited and the National Stock Exchange of India Limited.

Trading Window Status

The trading window for dealing in the securities of Jubilant Pharmova remains closed for designated persons and their immediate relatives. This restriction, which began on Wednesday, July 01, 2026, will continue until Wednesday, August 12, 2026, inclusive. The closure aligns with the company's Code of Conduct framed pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended. Designated persons have been informed of the extended closure period.

Key Dates

The company secretary, Naresh Kapoor, signed the intimation on August 5, 2026. The notice was issued from the company's registered office in Noida, Uttar Pradesh. As a Jubilant Bhartia Company, Jubilant Pharmova continues to adhere to regulatory disclosure norms despite the scheduling change.